Icotinib Hydrochloride is the hydrochloride salt form of icotinib, an orally available quinazoline-based inhibitor of EGFR, with potential antineoplastic activity.

CL 218872 is a benzodiazepine agonist displaying selectivity for α1 subunit-containing GABAA receptors (Ki values are 130, 1820, 1530, > 10000, 490 and > 10000 nM for α1, α2, α3, α4, α5 and α6-subunit containing receptors respectively).

Trachelogenin, an HCV entry inhibitor, has antiproliferative effects, and its mechanism is related to affecting the phosphorylation of key proteins in the β-Catenin signaling pathway, such as β-Catenin, c-Myc, and GSK3, in a concentration-dependent manner.